A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Clomiphene based ovarian stimulation in a commercial donor program
2015
Journal of Human Reproductive Sciences
for prolonged durations, leading to increased costs and adverse effect on oocyte quality. [1] Antagonist protocol, when used with GnRH agonist trigger, does reduce the risk of moderate to severe OHSS. The use of clomiphene seems another attractive alternative for donors as it may reduce the dose of stimulation and at the same time eliminate the need for the antagonist. Clomiphene based ovarian stimulation in a commercial donor program ABSTRACT OBJECTIVE: This study was conducted to compare an
doi:10.4103/0974-1208.165151
pmid:26538856
pmcid:PMC4601172
fatcat:gwwumswcvnggrdqzypx6x25fgy